News

Terri L. Clevenger

Terri L. Clevenger

Immediately after college, Terri L. Clevenger began working in the bustling city of Boston, Massachusetts doing public relations work overseeing the ‘Concerts on the Common’ program for a local firm. It was 1983 and she was eager to show the world just how strong and capable an educated woman can be in the corporate world.

Zephyr Health Named to 2017 Red Herring Top 100 North America

Zephyr Health Named to 2017 Red Herring Top 100 North America

SAN FRANCISCO – 6.19.2017 – Zephyr Health, the leading Insights-as-a-Service solution provider for Life Sciences companies, has been selected as a winner of Red Herring’s Top 100 North America award, for its innovative services and solutions. Zephyr Health’s patented machine learning automates the arduous process of linking the vast amount of disparate data available in healthcare today with internal customer data and purchased data to provide robust insights on physicians, accounts, and institutions for commercial transformation.

Zephyr Health and Decision Resources Group (DRG) Maximize Value of Formulary Data for Life Sciences Commercial Teams

Provider Market Access: A First-of-its-Kind, New Product Offering is Now Available

BURLINGTON, MA and SAN FRANCISCO, CA, June 12, 2017 — Zephyr Health, the leading Insights-as-a-Service solution provider for Life Sciences companies, and Decision Resources Group (DRG), one of the healthcare industry’s most trusted providers of market intelligence and global data products and services, today announced the release of Provider Market Access.

GeneCentric Therapeutics Appoints Walter M. Capone as Chief Business Officer and Adds Ellen Lubman to Board of Directors as Company Advances Drug Development Platform

GeneCentric Therapeutics Appoints Walter M. Capone as Chief Business Officer and Adds Ellen Lubman to Board of Directors as Company Advances Drug Development Platform

GeneCentric Therapeutics Appoints Walter M. Capone as Chief Business Officer and Adds Ellen Lubman to Board of Directors as Company Advances Drug Development Platform

DURHAM, NC, May 30, 2017-- GeneCentric Therapeutics, Inc., a precision medicine company dedicated to accelerating drug development by redefining the advanced classification of cancers, today announced the appointments of Walter M. Capone as Chief Business Officer and Ellen Lubman to the company’s Board of Directors.

Novaseek Research is Named Top 10 Clinical Data Management Solution Provider

Novaseek Research is Named Top 10 Clinical Data Management Solution Provider

CAMBRIDGE, MA, May 25, 2017– Novaseek Research Inc., a health IT for life sciences company, today announced that it was awarded the Top 10 Clinical Data Management Solution Provider 2017 award by Pharma Tech Outlook. The award recognizes 10 companies at the forefront of providing clinical data management solutions for the pharmaceutical industry and impacting the marketplace.

SERA PROGNOSTICS IS NAMED A 2017 SILVER EDISON AWARD WINNER

SERA PROGNOSTICS IS NAMED A 2017 SILVER EDISON AWARD WINNER

PreTRM® Test Wins at New York Ceremony; Awards Celebrate 30 Years of Honoring Innovators and Innovation

New York, NY – April 21, 2017 – The Edison Awards, celebrating 30 years of honoring the best in innovation and excellence in the development of new products and services, announced today that Sera Prognostics’ PreTRM Test was voted a Silver Winner for innovation in the “Health and Wellness” category at the April 20th event at The Capitale in New York City.

Novaseek Research Announces Partnership with CoxHealth to Advance Biomedical and Clinical Research

Novaseek Research Announces Partnership with CoxHealth to Advance Biomedical and Clinical Research

Partnership with Missouri Health System Further Expands Access to Biospecimens and Dynamic Real World Data for Research

CAMBRIDGE, MA, April 13, 2017– Novaseek Research Inc, a health IT for life sciences company, today announced it has partnered with CoxHealth, one of the nation’s top 100 integrated health systems, to support and expand biomedical and clinical research activity.